Today, PARP inhibitors are well-established drugs targeting HR-defective tumor cells and were clinically approved for treatment of platinum-sensitive and BRCA-mutated ovarian cancer patients [36, 52]. This evidence concerns the gene PARP1 and ovarian carcinoma.